Tag Archives: Life Science

Hot Investor Mandate 4: VC Firm with Offices in New England Seeks Digital Health Platform Companies Relating to Drug Discovery, Delivery, and Manufacturing

24 May

A venture capital firm with offices in the New England region currently manages four funds, two of which are dedicated to sector specific investments. The first focuses on healthcare and life science investments, while the other is focused on investing in built environment technology. On average, the initial size of investment is up to $1M, and the firm has the capacity to invest $2-4 M after the initial investment. The firm initially invests from Seed to Series A typically, but has come in at later stage investments. The firm is willing to lead in seed rounds and co-invest in later rounds. The firm has a preference for investing in US, but can invest globally. The firm is actively seeking new investment opportunities.

The firm is a flexible investor that is currently looking for life science platforms relating to drug discovery, delivery, and manufacturing and digital health companies. The firm typically does not invest in therapeutics, medical devices, and diagnostics. The firm prefers enterprise to direct-to-consumer health IT companies. In addition, the firm prefers companies that meet at least $1M revenue traction on the health IT side.

The firm will invest in privately held companies only. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , ,

Hot Investor Mandate 1: Firm Partnered with a Family Office Seeking to Provide Seed Capital to USA-Based Therapeutics Opportunities

17 May

A Chicago-based life sciences investment fund is focused on accelerating the growth of early-stage biotechnology and pharmaceutical companies. Partnered with a family investment office, the firm seeks to make 10 seed round investments within the next year. The firm will invest in companies based in the U.S.

The firm is seeking investments in biotech/therapeutics companies and is not interested in medical device or digital health technologies. The firm is interested in companies with assets or platform technologies in preclinical or early clinical development and is indication agnostic.

The firm does not have any company management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , ,

Hot Investor Mandate 2: Company Acquired by Chinese Pharma Seeks Early to Mid-Stage Therapeutics Partnering Opportunities, Capable of Investing Up to $100M

17 May

A spin-out pharmaceutical company recently acquired by a Chinese pharmaceutical company is seeking early to mid-stage technology for equity, in-licensing, and acquisition opportunities, and typically invests $10M to $100M per project depending on the opportunity. In the past several years, the company also acquired two USA companies at $200-300M range. The company is seeking opportunities on a global level.

The firm is interested in early to mid-stage therapeutics in inflammatory diseases, cardiovascular diseases, diabetes, and cancer. The firm seeks preclinical to clinical stage pharmaceuticals with particular interest in large molecule biologics including naturally derived molecules and fermentation based products.

The firm is open to talking with companies, including virtual organizations.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , ,

Hot Investor Mandate 3: California-Based VC Seeking to Invest in Therapeutic Technologies that Solve Problems Within Genetically Driven Diseases

17 May

A California-based firm backed by a number of well-known global funds is actively seeking investment opportunities. The firm prefers to be the first institutional investor in a company, and is typically an active, lead investor (often the sole investor). The firm typically invests in 5 opportunities per year.

The firm focuses on genetic drivers of disease, and therefore only invests in treatments for monogenic diseases or genetically-driven cancers. The firm is only interested in treatments that elicit a disease-modifying response; treatments that target symptoms of monogenic diseases are not of interest. Therapeutics must have a clearly-defined mechanism of action. The firm usually invests at the preclinical stage, up to 18 months prior to IND, but is open to later stage candidates (including clinical).

The firm focuses on individual products, not technology platforms. The firm typically houses each single asset in its own discrete subsidiary. The firm has internal expertise in medicinal chemistry, biology, and clinical trials, with personnel having significantly contributed to 30+ INDs and 10+ approved drugs. The company will often leverage internal expertise for subsidiaries, and can also assist with recruiting.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

Hot Investor Mandate 4: Chinese VC/PE Firm Works on Early and Late-Stage Deals in Medical Devices and Therapeutics with China Market Potential

17 May

A Shanghai-based venture capital/private equity firm manages both USD and RMB denominated funds. The firm invests in Series A rounds at $1-2M, though its sweet spot is investing $10-15M in Series B/C rounds. The firm works closely with local provincial Chinese governments, allowing them the ability to bring technology successfully into the Chinese market. The firm will generally not invest in the seed stage and seeks opportunities globally.

The firm invests in pharmaceuticals and Class II medical devices, including an interest in 505(b)(2) repurposed compounds, as well as healthcare-related industries. The firm is interested in all therapeutic areas and in early to mid-development stage companies. The firm focuses on unmet medical needs with a China market potential.

The firm does not have management team requirements. The firm will typically take a board seat post-investment, and has the capability to lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , ,

Hot Investor Mandate 3: San Francisco-based Large Global Private Investment Firm Seeking Early-Stage Therapeutics and Commercial-Stage Devices Worldwide

10 May

A large PE/VC is investing in life science innovation through its $5B Growth and Rise funds. The firm is a leading global private investment firm with over $59 billion AUM, based in San Francisco, California. The investment size typically ranges from $20M to $50M in equity. The firm is agnostic to company location or stage.

The firm aims to invest in therapeutics, commercial stage medical devices, and opportunistically in other innovative life sciences spaces. For therapeutics, the firm seeks small molecules and biologics and is open to all indications including orphan indications. The firm will consider products in all phases of clinical trials, from pre-clinical to phase III, and also commercial stage therapeutics. The firm is open to both PMA and 510K devices, as long as the device is already being sold at a commercial stage. The firm is also interested in services such as CROs and CMOs as well as tools of genomics and proteomics.

The firm invests for the long term, and is heavily involved in, and committed to, the growth and success of their portfolio companies. The firm, therefore, generally take a board seat/observer rights. The firm only invests in private companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

Hot Investor Mandate 4: Hong Kong-based Family Office Seeking Small Molecule Therapeutics, Devices, Diagnostics, and Healthcare IT Globally

10 May

A wholly-owned venture arm of a Hong-Kong based family is focused on making early stage life science investments across sectors such as new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and etc. The firm is managed by a team of investment professionals who are entrepreneurial, have deep scientific and industry knowledge and are effective in the environment in which they operate.

The firm seeks to invest in new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT etc. For therapeutics, the firm seeks novel small molecule and biologics and is agnostic in terms of indication. However, indications that address a large market in China are of interest. The firm looks for early stage assets in pre-clinical and phase I of clinical trials. However, the firm will not rule out assets in phase II. For devices, the firm is opportunistic in terms of the class of device.

The firm seeks an active role in its portfolio companies and generally obtain a seat on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , ,

← Older Entries
Newer Entries →